Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a biopharmaceutical company based in Conshohocken, Pennsylvania, that is focused on developing novel therapeutics for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). The company's first therapy has been granted accelerated approval by the FDA for the treatment of adults with NASH and is currently being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis.